Detailed Abstract
[E-poster - Liver (Liver Disease/Surgery)]
[EP 106] Treatment Strategies for Borderline Resectable Colorectal Liver Metastases
Yasuko MATSU0 1, Satoshi YASUDA 1, Shunsuke DOI 1, Takeshi SAKATA 1, Yuichiro KOHARA 1, Kota NAKAMURA 1, Minako NAGAI 1, Masayuki SHO 1
1 Surgery, Nara Medical University, JAPAN
Background : To identify the borderline resectable colorectal liver metastases (CRLM) from our database, and consider the usefulness of neoadjuvant chemotherapy (NAC) for patients with borderline CRLM.
Methods : (1) We identified the poor prognostic factors for the patients with CRLM who underwent upfront surgery (US) from 2000 to 2015. (2) We defined the borderline resectable cases as those with the above poor prognostic factors between 2005 and 2020, and classified into two group, the US group and the NAC group. We compared the OS between the two groups after propensity score matching (PSM).
Results : (1) Multivariate analysis showed that grade BC CRLM was identified as an independent poor prognostic factor. (2) Forty-two patients were in the US group, and 26 patients in the NAC group. After PSM, 18 patients were selected for each group. The 3-year DFS were 6.6%, and 11.1%, and the 3-year OS were 63.5%, and 73.5% in each group. There were no significant differences in the DFS or OS between the two groups. Adjuvant chemotherapy was performed in 9 patients (50%) in the US group and 11 patients (61.1%) in the NAC group. Median OS was 45.1 months in surgery alone group, 43.6 months in NAC alone group, and 50.2 months in adjuvant therapy alone group, and not reached in NAC+adjuvant therapy group. Better prognosis was obtained in NAC+adjuvant therapy group.
Conclusions : NAC for borderline resectable CRLM does not improve prognosis compared with US. Completion of perioperative chemotherapy may improve prognosis.
Methods : (1) We identified the poor prognostic factors for the patients with CRLM who underwent upfront surgery (US) from 2000 to 2015. (2) We defined the borderline resectable cases as those with the above poor prognostic factors between 2005 and 2020, and classified into two group, the US group and the NAC group. We compared the OS between the two groups after propensity score matching (PSM).
Results : (1) Multivariate analysis showed that grade BC CRLM was identified as an independent poor prognostic factor. (2) Forty-two patients were in the US group, and 26 patients in the NAC group. After PSM, 18 patients were selected for each group. The 3-year DFS were 6.6%, and 11.1%, and the 3-year OS were 63.5%, and 73.5% in each group. There were no significant differences in the DFS or OS between the two groups. Adjuvant chemotherapy was performed in 9 patients (50%) in the US group and 11 patients (61.1%) in the NAC group. Median OS was 45.1 months in surgery alone group, 43.6 months in NAC alone group, and 50.2 months in adjuvant therapy alone group, and not reached in NAC+adjuvant therapy group. Better prognosis was obtained in NAC+adjuvant therapy group.
Conclusions : NAC for borderline resectable CRLM does not improve prognosis compared with US. Completion of perioperative chemotherapy may improve prognosis.
SESSION
E-poster
E-Session 03/21 ALL DAY